.navbar .collapse { display: block; } .mobile-nav { max-height: none !important; } @media screen and (min-width: 1200px) { .navbar #basic-navbar-nav .navbar-nav { position: static !important; } }

BTK Inhibition for Waldenstrom Macroglobulinemia

EP. 1: The Nature of Waldenstrom Macroglobulinemia

February 15th 2019

EP. 2: Risk Factors in Developing Waldenstrom Macroglobulinemia

February 15th 2019

EP. 3: Waldenstrom Macroglobulinemia: Establishing a Diagnosis

February 15th 2019

EP. 4: Factors Impacting a Diagnosis and Prognosis of WM

February 15th 2019

EP. 5: Waldenstrom Macroglobulinemia: When to Initiate Therapy

February 15th 2019

EP. 6: A Historic Perspective on Frontline WM Management

February 15th 2019

EP. 7: Waldenstrom Macroglobulinemia: Evolving Frontline Treatment

February 15th 2019

EP. 8: Selecting Therapy Through Multiple Lines in WM

February 15th 2019

EP. 9: Targeted Approaches in Waldenstrom Macroglobulinemia

February 15th 2019

EP. 10: BTK Inhibitors in WM: Understanding Safety/Efficacy

February 15th 2019

EP. 11: Future Management of Waldenstrom Macroglobulinemia

February 15th 2019

Latest News

Living Well Beyond Bladder Cancer With Support

Expert Discusses Effects of a Bladder Cancer Diagnosis on Caregivers and the Support Available to Them

Patients Can Help Move the Needle Forward in Bladder Cancer Clinical Trials With Participation

Having Open and Honest Conversations With Oncologists Aids in Patient-Physician Communication in Bladder Cancer

View More Latest News